Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)

  • Technology appraisal
  • TA774
  • Published: 

History

Documents created during the development process.

Final scope

Final matrix

NICE?s response to comments on the draft scope and provisional matrix

Equality impact assessment

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: provisional scope

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: provisional matrix

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: draft scope for consultation (pre-referral) - November 2014

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide: provisional matrix (pre-referral) - November 2014